Duvelisib, an Oral Dual PI3K ‐δ, γ Inhibitor, Shows Clinical Activity in Indolent Non‐Hodgkin Lymphoma in a Phase 1 Study

American Journal of Hematology,Volume 0, Issue ja, -Not available-.

Source: American Journal of Hematology - July 23, 2018 Category: Hematology Authors: Ian W Flinn MD PhD , Manish Patel MD , Yasuhiro Oki MD , Steven Horwitz MD , Francine F Foss MD , Kerstin Allen MA , Mark Douglas MS , Howard Stern MD PhD , Jennifer Sweeney BS , Jahnavi Kharidia RPh , Patrick Kell Source Type: research